{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:14:53Z","timestamp":1784049293813,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mugla Sitki KocmanUniversity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    RICTOR, a scaffold protein of the mTORC2 complex, regulates AKT signaling and has been implicated in tumor progression and therapy resistance across multiple cancers. However, the prognostic impact of RICTOR mutations in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma remains unclear. This study aimed to evaluate the clinicopathological, molecular, and survival characteristics of patients with metastatic EGFR-mutant lung adenocarcinoma according to RICTOR mutation status. We retrospectively analyzed 235 patients diagnosed with de novo metastatic lung adenocarcinoma between 2018 and 2024 across three tertiary oncology centers. Patients with targetable oncogenic drivers other than EGFR (ALK, ROS1, HER2, KRAS G12C, BRAF V600E, RET, MET) were excluded. Next-generation sequencing (NGS) was performed using a hybrid-capture panel (Illumina TSO500). Clinical features, co-mutations, treatment responses, and overall survival (OS) were compared between RICTOR-mutant and wild-type subgroups within the EGFR-mutant cohort. Survival analyses employed Kaplan\u2013Meier estimates, log-rank tests, and Cox regression modeling. Of the total cohort, 39 patients (17%) had EGFR-mutant tumors, of whom 15 (38%) carried RICTOR mutations. RICTOR-mutant cases were more likely to be former smokers and presented more frequently with bone and pleural metastases compared with wild type. Treatment patterns and RECIST v1.1 response rates did not significantly differ between groups. Median OS was significantly shorter in RICTOR-mutant versus RICTOR-wild patients (8 vs. 14 months, log-rank\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In univariate analysis, RICTOR mutations were associated with inferior OS (HR 2.48, 95% CI 1.73\u20137.95,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03), and this association remained significant in multivariate analysis (HR 2.34, 95% CI 1.69\u20136.75,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021). Exploratory analyses suggested that RICTOR co-mutations with EGFR exon 19 deletions, exon 18 alterations, or exon 20 alterations were associated with poorer survival outcomes. RICTOR mutations were associated with a high-risk subset of EGFR-mutant metastatic lung adenocarcinoma characterized by more aggressive clinical features and worse survival. These findings suggest the need for prospective validation and support the potential integration of RICTOR status into molecular risk stratification frameworks for precision oncology.\n                  <\/jats:p>","DOI":"10.1007\/s00428-026-04559-2","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:35:00Z","timestamp":1777887300000},"page":"79-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study"],"prefix":"10.1007","volume":"489","author":[{"given":"Ali","family":"Aytac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkay Mehmet","family":"Ozata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Halil","family":"Erdogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-7284","authenticated-orcid":false,"given":"Ozgur","family":"Tanriverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"1","key":"4559_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4559_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","volume":"10","author":"H Padinharayil","year":"2022","unstructured":"Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M et al (2022) Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis 10(3):960\u2013989. https:\/\/doi.org\/10.1016\/j.gendis.2022.07.023","journal-title":"Genes Dis"},{"key":"4559_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611715","volume":"30","author":"G G\u00e1lffy","year":"2024","unstructured":"G\u00e1lffy G, Mor\u00f3cz \u00c9, Korompay R, H\u00e9cz R, Bujdos\u00f3 R, Pusk\u00e1s R et al (2024) Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res 30:1611715. https:\/\/doi.org\/10.3389\/pore.2024.1611715","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"4559_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y et al (2024) Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther 9(1):132. https:\/\/doi.org\/10.1038\/s41392-024-01823-2","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"4559_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162882","volume":"16","author":"A Rina","year":"2024","unstructured":"Rina A, Maffeo D, Minnai F, Esposito M, Palmieri M, Serio VB et al (2024) The genetic analysis and clinical therapy in lung cancer: current advances and future directions. Cancers 16(16):2882. https:\/\/doi.org\/10.3390\/cancers16162882","journal-title":"Cancers"},{"issue":"1","key":"4559_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M (2024) Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther 9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x","journal-title":"Signal Transduct Target Ther"},{"key":"4559_CR7","doi-asserted-by":"publisher","DOI":"10.2196\/64399","volume":"11","author":"AJM Brnabic","year":"2025","unstructured":"Brnabic AJM, Lipkovich I, Kadziola Z, He D, Krein PM, Hess LM (2025) Next-generation sequencing-based testing among patients with advanced or metastatic nonsquamous non-small cell lung cancer in the United States: predictive modeling using machine learning methods. JMIR Cancer 11:e64399. https:\/\/doi.org\/10.2196\/64399","journal-title":"JMIR Cancer"},{"issue":"4","key":"4559_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A (2021) Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol 12(4):217\u2013237. https:\/\/doi.org\/10.5306\/wjco.v12.i4.217","journal-title":"World J Clin Oncol"},{"issue":"1","key":"4559_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi N, Heidari R, Farhadi A, Chamanara M, Farahani N, Vahidi M et al (2025) Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov Oncol 16(1):578. https:\/\/doi.org\/10.1007\/s12672-025-01816-9","journal-title":"Discov Oncol"},{"key":"4559_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2022.11.002","volume":"174","author":"D Heredia","year":"2022","unstructured":"Heredia D, Mas L, Cardona AF, Oyervides V, Motta Guerrero R, Galvez-Nino M et al (2022) A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: data from LATAM population. Lung Cancer 174:133\u2013140. https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.002","journal-title":"Lung Cancer"},{"issue":"1","key":"4559_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04075-1","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Ni Y, Lv F, Shi Y, Chen Y, Wu X et al (2025) Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions. BMC Med 23(1):249. https:\/\/doi.org\/10.1186\/s12916-025-04075-1","journal-title":"BMC Med"},{"issue":"1","key":"4559_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14016-z","volume":"25","author":"FY Wang","year":"2025","unstructured":"Wang FY, Yeh YC, Lin SY, Wang SY, Chen PC, Chou TY et al (2025) Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer. BMC Cancer 25(1):715. https:\/\/doi.org\/10.1186\/s12885-025-14016-z","journal-title":"BMC Cancer"},{"issue":"12","key":"4559_CR13","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1021\/acsptsci.4c00530","volume":"7","author":"D Mehta","year":"2024","unstructured":"Mehta D, Rajput K, Jain D, Bajaj A, Dasgupta U (2024) Unveiling the role of mechanistic target of rapamycin kinase (MTOR) signaling in cancer progression and the emergence of MTOR inhibitors as therapeutic strategies. ACS Pharmacol Transl Sci 7(12):3758\u20133779. https:\/\/doi.org\/10.1021\/acsptsci.4c00530","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"9","key":"4559_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/genes11091045","volume":"11","author":"W Fu","year":"2020","unstructured":"Fu W, Hall MN (2020) Regulation of mTORC2 signaling. Genes 11(9):1045. https:\/\/doi.org\/10.3390\/genes11091045","journal-title":"Genes"},{"issue":"12","key":"4559_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1158\/2159-8290.CD-14-0971","volume":"5","author":"H Cheng","year":"2015","unstructured":"Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B et al (2015) RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1\/2 inhibitors. Cancer Discov 5(12):1262\u201370. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0971","journal-title":"Cancer Discov"},{"issue":"3","key":"4559_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030543","volume":"16","author":"F Szalai","year":"2024","unstructured":"Szalai F, Sztankovics D, Krencz I, Moldvai D, P\u00e1pay J, Sebesty\u00e9n A et al (2024) Rictor-a mediator of progression and metastasis in lung cancer. Cancers (Basel) 16(3):543. https:\/\/doi.org\/10.3390\/cancers16030543","journal-title":"Cancers (Basel)"},{"issue":"18","key":"4559_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14182090","volume":"14","author":"M Beckert","year":"2024","unstructured":"Beckert M, Meyer C, Papadopoulos T, Levidou G (2024) Application of the 5th WHO guidelines for the diagnosis of lung carcinoma in small lung biopsies in a tertiary care center: is insecurity of pathologists for the accurate diagnosis justified? Diagn 14(18):2090. https:\/\/doi.org\/10.3390\/diagnostics14182090","journal-title":"Diagn"},{"issue":"2","key":"4559_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/10668969231171940","volume":"32","author":"LM Briski","year":"2024","unstructured":"Briski LM, Aron M, Epstein JI, Russell DH, Assarzadegan N, Delma KS et al (2024) Patterns of immunoreactivity with TTF-1 antibodies 8G7G3\/1 and SPT24 suggest distinct immunoprofiles between most pulmonary and nonpulmonary small cell carcinomas. Int J Surg Pathol 32(2):230\u2013238","journal-title":"Int J Surg Pathol"},{"key":"4559_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/LCTT.S181406","volume":"10","author":"S Kate","year":"2019","unstructured":"Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R et al (2019) Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl) 10:1\u201310. https:\/\/doi.org\/10.2147\/LCTT.S181406","journal-title":"Lung Cancer (Auckl)"},{"issue":"D1","key":"4559_CR20","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita, McLaren K et al (2024) COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res 52(D1):D1210\u2013D1217. https:\/\/doi.org\/10.1093\/nar\/gkad986","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"4559_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","volume":"15","author":"S Lantuejoul","year":"2020","unstructured":"Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC et al (2020) PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol 15(4):499\u2013519. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.107","journal-title":"J Thorac Oncol"},{"key":"4559_CR22","doi-asserted-by":"publisher","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, FLAURA Investigators et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","DOI":"10.1056\/NEJMoa1713137"},{"key":"4559_CR23","doi-asserted-by":"publisher","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, FLAURA Investigators et al (2020) Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","DOI":"10.1056\/NEJMoa1913662"},{"issue":"11","key":"4559_CR24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S et al (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454\u20131466. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"issue":"27","key":"4559_CR25","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327\u201334. https:\/\/doi.org\/10.1200\/JCO.2012.44.2806","journal-title":"J Clin Oncol"},{"issue":"7","key":"4559_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA et al (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"4559_CR27","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.2147\/CMAR.S287466","volume":"13","author":"D Peng","year":"2021","unstructured":"Peng D, Shan D, Dai C, Li J, Wang Z, Huang Z et al (2021) Real-world data on Osimertinib in Chinese patients with pretreated, EGFR T790M mutation positive, advanced non-small cell lung cancer: a retrospective study. Cancer Manag Res 13:2033\u20132039. https:\/\/doi.org\/10.2147\/CMAR.S287466","journal-title":"Cancer Manag Res"},{"key":"4559_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611643","volume":"30","author":"D Sztankovics","year":"2024","unstructured":"Sztankovics D, Moldvai D, Pet\u0151v\u00e1ri G, Dank\u00f3 T, Szalai F, Miyaura R et al (2024) mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies. Pathol Oncol Res 30:1611643. https:\/\/doi.org\/10.3389\/pore.2024.1611643","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"4559_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0794-0","volume":"17","author":"A Jebali","year":"2018","unstructured":"Jebali A, Dumaz N (2018) The role of RICTOR downstream of receptor tyrosine kinase in cancers. Mol Cancer 17(1):39. https:\/\/doi.org\/10.1186\/s12943-018-0794-0","journal-title":"Mol Cancer"},{"issue":"9","key":"4559_CR30","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-10-4058","volume":"71","author":"P Gulhati","year":"2011","unstructured":"Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M et al (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71(9):3246\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4058","journal-title":"Cancer Res"},{"key":"4559_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101364","volume":"18","author":"MJ Sanaei","year":"2022","unstructured":"Sanaei MJ, Razi S, Pourbagheri-Sigaroodi A, Bashash D (2022) The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles. Transl Oncol 18:101364. https:\/\/doi.org\/10.1016\/j.tranon.2022.101364","journal-title":"Transl Oncol"},{"key":"4559_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113985","volume":"202","author":"H Cao","year":"2024","unstructured":"Cao H, Ma Z, Huang Q, Han H, Li Y, Zhang Y et al (2024) Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma. Eur J Cancer 202:113985. https:\/\/doi.org\/10.1016\/j.ejca.2024.113985","journal-title":"Eur J Cancer"},{"issue":"9","key":"4559_CR33","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M et al (2017) Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res 23(9):2195\u20132202. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0966","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4559_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10020-020-0146-6","volume":"26","author":"D Zhao","year":"2020","unstructured":"Zhao D, Jiang M, Zhang X, Hou H (2020) The role of RICTOR amplification in targeted therapy and drug resistance. Mol Med 26(1):20. https:\/\/doi.org\/10.1186\/s10020-020-0146-6","journal-title":"Mol Med"},{"issue":"74","key":"4559_CR35","doi-asserted-by":"publisher","first-page":"33995","DOI":"10.18632\/oncotarget.26129","volume":"9","author":"D Ruder","year":"2018","unstructured":"Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H et al (2018) Concomitant targeting of the mTOR\/MAPK pathways: novel therapeutic strategy in subsets of RICTOR\/KRAS-altered non-small cell lung cancer. Oncotarget 9(74):33995\u201334008. https:\/\/doi.org\/10.18632\/oncotarget.26129","journal-title":"Oncotarget"},{"issue":"7","key":"4559_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tem.2014.04.002","volume":"25","author":"K Masui","year":"2014","unstructured":"Masui K, Cavenee WK, Mischel PS (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25(7):364\u2013373. https:\/\/doi.org\/10.1016\/j.tem.2014.04.002","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"4559_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100847","volume":"13","author":"SY Sun","year":"2020","unstructured":"Sun SY (2020) Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl Oncol 13(12):100847. https:\/\/doi.org\/10.1016\/j.tranon.2020.100847","journal-title":"Transl Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04559-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04559-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04559-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:02:43Z","timestamp":1784048563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04559-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4559"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04559-2","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Medical Sciences Ethics Committee of Mugla Sitki Kocman University (Ethics Committee Approval Number: 240038, Date: September 11, 2024). All procedures were conducted following the ethical principles outlined in the Declaration of Helsinki. This article was derived from Dr. B.M.O\u2019s internal medicine specialization thesis, after a petition for amendment was submitted within the framework of the same ethics committee.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the study, informed consent was waived by Medical Sciences Ethics Committee of Mugla Sitki Kocman University.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}